Pseudoexfoliation and Alzheimer’s associated CLU risk variant, rs2279590, lies within an enhancer element and regulates CLU, EPHX2 and PTK2B gene expression

Genetic variants at PTK2B-CLU locus pose as high-risk factors for many age-related disorders. However, the role of these variants in disease progression is less characterized. In this study, we aimed to investigate the functional significance of a clusterin intronic SNP, rs2279590, that has been associated with pseudoexfoliation, Alzheimer's disease (AD) and diabetes. We have previously shown that the alleles at rs2279590 differentially regulate clusterin (CLU) gene expression in lens capsule tissues. This polymorphism resides in an active regulatory region marked by H3K27Ac and DNase I hypersensitive site and is an eQTL for CLU expression. Here, we report the presence of an enhancer element in surrounding region of rs2279590. Deletion of a 115 bp intronic region flanking the rs2279590 variant through CRISPR-Cas9 genome editing in HEK293 cells demonstrated a decreased clusterin gene expression. Electrophoretic mobility shift and chromatin immunoprecipitation assays show that rs2279590 with allele 'A' constitutes a transcription factor binding site for heat shock factor-1 (HSF1) but not with allele 'G'. By binding to allele 'A', HSF1 abrogates the enhancer effect of the locus as validated by reporter assays. Interestingly, rs2279590 locus has a widespread enhancer effect on two nearby genes, protein tyrosine kinase 2 beta (PTK2B) and epoxide hydrolase-2 (EPHX2); both of which have been previously associated with AD as risk factors. To summarize, our study unveils a mechanistic role of the common variant rs2279590 that can affect a variety of aging disorders by regulating the expression of a specific set of genes.

[1]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[2]  H. Soininen,et al.  Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology , 2016, Molecular Psychiatry.

[3]  Mohan Giri,et al.  Genes associated with Alzheimer’s disease: an overview and current status , 2016, Clinical interventions in aging.

[4]  C. Dobson,et al.  The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  S. Bassett,et al.  Alzheimer's risk variants in the clusterin gene are associated with alternative splicing , 2011, Translational Psychiatry.

[6]  G. Naumann,et al.  Clusterin deficiency in eyes with pseudoexfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material. , 2006, Investigative ophthalmology & visual science.

[7]  Keith A. Johnson,et al.  Modulation of TREM2 by CD33: a protein QTL study integrates Alzheimer loci in human monocytes , 2015, Nature Neuroscience.

[8]  Takeo Kato,et al.  Association of the clusterin gene polymorphisms with type 2 diabetes mellitus. , 2011, Metabolism: clinical and experimental.

[9]  You-Qiang Song,et al.  Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer's disease in a southern Chinese population , 2012, Neurobiology of Aging.

[10]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[11]  Albert Hofman,et al.  Plasma clusterin and the risk of Alzheimer disease. , 2011, JAMA.

[12]  N. Alkayed,et al.  Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. , 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  L. Sistonen,et al.  Regulation of HSF1 function in the heat stress response: implications in aging and disease. , 2011, Annual review of biochemistry.

[14]  H. Cai,et al.  NEDD4-mediated HSF1 degradation underlies α-synucleinopathy , 2015, Human molecular genetics.

[15]  Bruce J Aronow,et al.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Jomary,et al.  Clusterin , 2019, Springer Reference Medizin.

[17]  Lisa M. Ryno,et al.  The Systemic Amyloid Precursor Transthyretin (TTR) Behaves as a Neuronal Stress Protein Regulated by HSF1 in SH-SY5Y Human Neuroblastoma Cells and APP23 Alzheimer's Disease Model Mice , 2014, The Journal of Neuroscience.

[18]  U. Schlötzer-Schrehardt,et al.  Exploring functional candidate genes for genetic association in german patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. , 2009, Investigative ophthalmology & visual science.

[19]  J. Renger,et al.  Intracellular Clusterin Interacts with Brain Isoforms of the Bridging Integrator 1 and with the Microtubule-Associated Protein Tau in Alzheimer's Disease , 2014, PloS one.

[20]  M E Rosenberg,et al.  Clusterin: physiologic and pathophysiologic considerations. , 1995, The international journal of biochemistry & cell biology.

[21]  Z. Ye,et al.  Increased heat shock transcription factor 1 in the cerebellum reverses the deficiency of Purkinje cells in Alzheimer's disease , 2013, Brain Research.

[22]  E. Crawford,et al.  Reduced Insulin/IGF-1 Signaling Restores the Dynamic Properties of Key Stress Granule Proteins during Aging , 2017, Cell reports.

[23]  S. D’Mello,et al.  HSF1 Protects Neurons through a Novel Trimerization- and HSP-Independent Mechanism , 2014, The Journal of Neuroscience.

[24]  T. Czerny,et al.  An artificial HSE promoter for efficient and selective detection of heat shock pathway activity , 2014, Cell Stress and Chaperones.

[25]  D. Thiele,et al.  Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases , 2011, Nature Reviews Drug Discovery.

[26]  A. Goate,et al.  Expression of Novel Alzheimer’s Disease Risk Genes in Control and Alzheimer’s Disease Brains , 2012, PloS one.

[27]  M. Scaltriti,et al.  Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin. , 2004, The Biochemical journal.

[28]  Debananda Padhi,et al.  Role of an extracellular chaperone, Clusterin in the pathogenesis of Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma. , 2014, Experimental eye research.

[29]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[30]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[31]  D. Boothman,et al.  Advances and challenges in basic and translational research on clusterin. , 2009, Cancer research.

[32]  Henrik Zetterberg,et al.  Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism , 2016, Acta Neuropathologica.

[33]  R. Petersen,et al.  Low neural exosomal levels of cellular survival factors in Alzheimer’s disease , 2015, Annals of clinical and translational neurology.

[34]  Y. Kitaura,et al.  Active HSF1 Significantly Suppresses Polyglutamine Aggregate Formation in Cellular and Mouse Models* , 2005, Journal of Biological Chemistry.

[35]  J. Götz,et al.  Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice , 2013, Neurobiology of Aging.

[36]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[37]  G. Gouras.  mTOR: at the crossroads of aging, chaperones, and Alzheimer's disease , 2013, Journal of neurochemistry.